![](https://news.europawire.eu/wp-content/uploads/2016/08/SHIRE-LOGO-144x144.jpg)
Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites Lexington, Mass., 14-Sep-2016 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug … Read the full press release